[Dosage schedule of new anticancer drugs--evaluation of the use of 3 anticancer drugs in the study of phases 1 and 2].
D000284:Administration, Oral; D000577:Amides / Q000008:administration & dosage / Q000009:adverse effects / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001389:Azirines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000633:toxicity; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects*; D017976:Phosphorus Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000633:toxicity; D011809:Quinones / Q000008:administration & dosage* / Q000009:adverse effects* / Q000633:toxicity; D051381:Rats; D013830:Thiadiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000633:toxicity
D000577:Amides; D000970:Antineoplastic Agents; D001389:Azirines; D010455:Peptides; D017976:Phosphorus Acids; D011809:Quinones; D013830:Thiadiazoles